RossiJ, et al.Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood, 2018; 132 (8): 804–814.
2.
ZhuH, et al.Metabolic Reprogramming via Depletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. Cell Stem Cell, 2020; 27: 1–14.
3.
SchmidtA, et al.Rational design of a trimeric APRILbased CAR-binding domain enables efficient targeting of multiple myeloma. Blood Advances, 2019; 3(21): 3248–60.
4.
SpiegelJ, et al.CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021.
